<PAGE>
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF A FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Director's Share Purchase on September 28th 2000
GEMINI GENOMICS PLC
(Translation of registrant's name into English)
162 SCIENCE PARK,
MILTON ROAD,
CAMBRIDGE,
CB4 OGH.
ENGLAND
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.)
FORM 20-F X FORM 40-F
(Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
YES NO X
(If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2 (b): N/A)
<PAGE>
Today, September 28, Paul Kelly, Chief Executive Officer of Gemini Genomics plc,
purchased 1,000 ADSs in the open market. The average purchase price was $14.625
Gemini Genomics maintains a company policy, on a voluntary basis, to disclose
purchases or sales by officers and directors of shares or ADSs of Gemini
Genomics plc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
GEMINI GENOMICS PLC
(Registrant)
Date: September 28, 2000 By: /s/ Roger Dickinson
Mr Roger Dickinson
Chief Corporate Officer
